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Enhanced Capillary Amyloid Angiopathy-Associated Pathology
in Tg-SwDI Mice With Deleted Nitric Oxide Synthase 2
William E. Van Nostrand, PhD; Feng Xu, MD;
Annemieke J.M. Rozemuller, MD, PhD; Carol A. Colton, PhD
Background and Purpose—Cerebral amyloid angiopathy Type 1 is characterized by amyloid  protein deposition along
cerebral capillaries and is accompanied by perivascular neuroinflammation and accumulation of phospho-tau protein.
Tg-SwDI mice recapitulate capillary amyloid deposition and associated neuroinflammation but lack accumulation of
perivascular phospho-tau protein.
Methods—Tg-SwDI mice were bred onto a nitric oxide synthase 2 gene knockout background and aged for 1 year. Brains
were harvested and analyzed using immunohistochemical and quantitative stereological methods to determine the extent
of capillary amyloid deposition, perivascular activated microglia, and cell-specific accumulation of phospho-tau protein.
Similar methods were also used to compare Tg-SwDI/NOS2/ and human cerebral amyloid angiopathy Type 1 brain
tissues.
Results—The absence of nitric oxide synthase 2 gene had no effect on the regional pattern or frequency of capillary
cerebral amyloid angiopathy or the numbers of perivascular activated microglia in Tg-SwDI mice. On the other hand,
Tg-SwDI/NOS2/ mice accumulated phospho-tau protein in perivascular neurons and activated microglia. Tg-SwDI/
NOS2/ mice exhibited a very similar distribution of capillary amyloid, activated microglia, and perivascular
phospho-tau protein as seen in human cerebral amyloid angiopathy Type 1.
Conclusions—These findings indicate that Tg-SwDI/NOS2/ mice more fully recapitulate the pathological changes
observed with capillary amyloid in human cerebral amyloid angiopathy Type 1. (Stroke. 2010;41[suppl 1]:S135-S138.)
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Cerebral amyloid angiopathy (CAA) is a condition char-acterized by accumulation of fibrillar amyloid  protein
deposits in blood vessels of the brain of patients with
Alzheimer disease and related disorders.1 Amyloid  is a 4
kDa peptide that is derived from its parent protein, the
amyloid  protein precursor (APP), through the sequential
processing by - and g-secretase enzymes.2 CAA presents as
2 subtypes: the more common CAA Type 2 affects arterioles
and arteries of the cortex and leptomeninges, whereas the less
common CAA Type 1 affects cerebral capillaries with or
without larger cerebral vessel involvement.3 Capillary fibril-
lar amyloid deposition in CAA Type 1 is accompanied by a
localized robust neuroinflammatory response and perivascu-
lar phospho-tau protein accumulation that is not commonly
associated with the affected larger vessels in CAA Type 2.
Previously, we generated a unique transgenic mouse, known
as Tg-SwDI, that expresses in brain human APP harboring
tandem Dutch (E22Q) and Iowa (D23N) amyloid  mutations
associated with familial forms of CAA.4 Tg-SwDI mice were
shown to develop early-onset and regionally extensive capil-
lary amyloid with associated neuroinflammation reminiscent
of CAA Type 1.4,5
Nitric oxide synthase 2 (NOS2), the inducible form of
nitric oxide synthase, is 1 of 3 isoforms of nitric oxide
synthase that are responsible for generating nitric oxide.6
Nitric oxide has been reported to possess both cytotoxic and
cytoprotective activities depending on its concentration and
cellular targets.7 Recently, we showed that breeding Tg-SwDI
mice onto a NOS2 deletion background (NOS2/) resulted
in more severe capillary CAA-related pathology, including
perivascular accumulation of phospho-tau protein, neuronal
loss, and greater behavioral impairments.8 In the present
study, we determined if the absence of NOS2 affected the
frequency of capillary CAA and associated microglial acti-
vation in Tg-SwDI mice. We also evaluated what cell types
exhibit perivascular phospho-tau accumulation in Tg-SwDI/
NOS2/ mice and how these pathologies directly compare
with human capillary CAA Type 1.
Methods
Transgenic Mice
All work with animals followed National Institutes of Health
guidelines and was approved by the Stony Brook University Insti-
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tutional Animal Care and Use Committee. The generation and
characterization of Tg-SwDI and Tg-SwDI/NOS2/ mice was
performed in our laboratory as previously described.4,5 For the
experiments, mice were aged to 12 months before euthanasia and
collection of brain tissue for analysis.
Immunohistochemical Analysis
Immunostainings of mouse and human brain tissues were performed
on deparaffinized sections or fresh-frozen sections as described.9 The
following antibodies were used: rabbit polyclonal antibody to colla-
gen Type IV for identification of blood vessels (1:100; Research
Diagnostics Inc, Flanders, NJ); monoclonal antibody AT8 for de-
tecting phospho-tau protein (1:250; Thermo Fisher Scientific);
monoclonal antibody NeuN for identification of neurons (1:500;
Chemicon); monoclonal antibody to glial fibrillary acidic protein for
identification of astrocytes (1:1000; Chemicon); and monoclonal
antibody to Major Histocompatibility Complex Class II for identifi-
cation of activated microglia (1:200; BD Pharmingen, San Jose,
Calif). Thioflavin-S staining for fibrillar amyloid was performed as
described.9
Quantitative Analysis of Regional Capillary CAA
and Activated Microglia
The percentage of thioflavin-S-labeled blood vessels and immuno-
stained-activated microglia in the regions of the thalamus and
frontotemporal cortex was, respectively, quantified on the same set
of systematically sampled thioflavin-S-stained sections using the
Stereologer software system (Systems Planning and Analysis) as
described.5,10
Results
Immunohistochemical analysis to identify capillary fibrillar
amyloid and the frequency of these deposits was measured
using stereological methods. As shown in Figure 1, a similar
pattern of capillary amyloid deposition in Tg-SwDI and
Tg-SwDI/NOS2/ mice was observed (Figures 1A and 1B,
respectively) with no quantitative difference in the regional
frequency of affected capillaries (Figure 1C). Similarly, a
common pattern of capillary-associated activated microglia
was observed in Tg-SwDI and Tg-SwDI/NOS2/ mice
(Figures 1D and 1E, respectively), again with no difference in
the regional densities of these neuroinflammatory cells (Fig-
ure 1F). These findings indicate that the absence of NOS2
does not affect capillary CAA and associated activated
microglia in Tg-SwDI mice.
Figure 1. Quantitation of brain capillary
amyloid frequency and associated acti-
vated microglia in Tg-SwDI mice and
Tg-SwDI/NOS2/ mice. Brain sections
from 12-month-old Tg-SwDI mice (A and
D) or Tg-SwDI/NOS2/ (B and E) mice
were immunolabeled for collagen Type IV
to identify capillaries (red) and stained
with thioflavin S (green) to identify fibrillar
amyloid (A and B) or immunolabeled for
MHC II (brown) to identify activated
microglia (D and E). Scale bar100 m.
Quantitative stereological measurement of
capillary amyloid frequency (C) and acti-
vated microglia densities (F) in thalamus
and cortex of Tg-SwDI mice (gray bars)
and Tg-SwDI/NOS2/ mice (black bars).
Data shown are the meanSD (n6 mice
for each group).
Figure 2. Immunolabeling for hyperphosphorylated tau colocalizes with perivascular neurons and activated microglia in Tg-SwDI/
NOS2/ mice. Brain sections from 12-month-old Tg-SwDI mice or Tg-SwDI/NOS2/ mice were immunolabeled for hyperphosphory-
lated tau using AT8 antibody (green). Neurons were identified using NeuN antibody (A to D), astrocytes using GFAP antibody (E to H),
and activated microglia using the MHC II antibody (I to L). Scale bars20 m.
S136 Stroke October 2010
 at Vrije on July 11, 2011http://stroke.ahajournals.org/Downloaded from 
Previously we reported that perivascular AT8-positive
phospho-tau protein accumulates in Tg-SwDI/NOS2/
mice.8 However, the specific cell types that accumulated
phospho-tau were not thoroughly determined. Therefore,
brain sections from Tg-SwDI and Tg-SwDI/NOS2/ mice
were double-immunolabeled for AT8 phospho-tau and mark-
ers specific for neurons, astrocytes, or activated microglia. As
shown in Figure 2, AT8 phospho-tau labeling was only
observed in Tg-SwDI/NOS2/ mice. Colocalization of AT8
phospho-tau labeling was observed in cortical neurons and
some thalamic neurons (Figures 2C and 2D, respectively). In
contrast, no colocalization of AT8 phospho-tau was observed
with astrocytes (Figure 2G–2H). However, strong colocaliza-
tion of AT8 phospho-tau was observed in some cortical but
many thalamic activated microglia that are tightly associated
with capillary amyloid deposits (Figures 2K and 2L, respec-
tively). These results indicate that AT8 phospho-tau is present
in some perivascular neurons and many activated microglia in
regions of capillary amyloid deposition in Tg-SwDI/
NOS2/ mice.
Capillary amyloid and associated pathology observed in
Tg-SwDI/NOS2/ mice were compared with human CAA
Type 1 brain tissues using immuno- and histochemical
stainings. Thioflavin S staining revealed a very similar
pattern of capillary amyloid accumulation in Tg-SwDI/
NOS2/ mice and human CAA type-1 (Figures 3A and 3D,
respectively). Furthermore, the capillary amyloid-associated
accumulation of perivascular activated microglia and
perivascular phospho-tau in Tg-SwDI/NOS2/ mouse
brain (Figures 3B and 3C, respectively) was highly remi-
niscent of that seen in the human CAA Type 1 brain
(Figures 3E and 3F, respectively). These findings show
that Tg-SwDI/NOS2/ mice recapitulate several key
features of capillary amyloid and associated pathological
changes observed in human CAA Type 1.
Discussion
In the present study, we show that Tg-SwDI/NOS2/
mice exhibit many of the pathological features of capillary
amyloid found in human CAA Type 1. The absence of
NOS2 does not affect the regional distribution or fre-
quency of capillary amyloid deposition nor the levels of
associated activated microglia in Tg-SwDI mice. However,
we previously reported that in the absence of NOS2, the
Tg-SwDI mice show additional pathological features, in-
cluding perivascular phospho-tau, neuronal loss, and
greater behavioral deficits.8 Here we further investigated
which types of perivascular cells exhibit AT8-positive
phospho-tau accumulation. Although some cortical neu-
rons showed labeling for phospho-tau, we found strong
labeling of perivascular activated microglia, particularly in
the thalamic region that is affected with a high frequency
of capillary amyloid. Although expression of phospho-tau
is largely expected in neurons in neurodegenerative con-
ditions, in mice, activated microglia have been reported to
express and accumulate tau protein after episodes of
ischemic injury.11 Whether this finding of microglial
phospho-tau presentation is restricted to Tg-SwDI/
NOS2/ mice or also observed in human cases of CAA
Type 1 remains to be further evaluated. In any case, the
findings presented in this study suggest that Tg-SwDI/
NOS2/ mice recapitulate many of the pathological
features of human CAA Type 1 and provide a valuable in
vivo model to further investigate this condition.
Sources of Funding
This work was supported in part by National Institutes of Health
grants RO1-NS55118 and RO1-AG23084.
Disclosures
None.
Figure 3. Brain capillary amyloid deposition and associated pathology in Tg-SwDI/NOS2/ mice and human CAA Type 1. Brain sec-
tions from 12-month-old Tg-SwDI/NOS2/ mice (A and B) and a case of human CAA Type 1 (D and E) were immunolabeled for colla-
gen Type IV to identify capillaries (red) and stained with thioflavin S (green) to identify fibrillar amyloid (A and D) or immunolabeled for
MHC II (brown) to identify activated microglia (B and E). Scale bars50 m. Similarly, brain sections from 12-month-old Tg-SwDI/
NOS2/ mice (C) and a case of human CAA Type 1 (F) were immunolabeled for hyperphosphorylated tau using AT8 antibody (red)
and stained with thioflavin S (green) to identify fibrillar amyloid. Scale bars20 m.
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